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Nucleoside analogues previously found to be inactive against the human immunodeficiency virus (HIV) may be activated by simple chemical 
derivatisation. As part of our effort to deliver masked phosphates inside living cells we have discovered that certain phosphate triester derivatives 
of inactive nucleoside analogues become inhibitors of HIV replication. This discovery underlies the importance of the masked phosphate approach, 
and has significant implications for the future design of chemotherapeutic nucleoside analogues. If highly modified nucleoside analogues may be 
active without the intervention of nucleoside kinase enzymes, major advantage may accrue in terms of low toxicity and enhanced selectivity. 
Moreover, the increased structural freedom may have implications for dealing with the emergence of resistance. The concept herein described as 
‘kinase bypass’ may thus stimulate the discovery of a new generation of antiviral agents. 
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1. INTRODUCTION 
Although nucleoside analogues, such as zidovudine 
(see Fig. 1, la) continue to dominate anti-HIV drug 
therapy they have a number of major limitations; such 
as their inherent toxicity, a dependence on kinase medi- 
ated activation to generate the bio-active (tri)phosphate 
forms, and the emergence of resistance [l-2]. There re- 
mains the need for potent and selective agents acting by 
different mechanisms and on novel targets during the 
process of viral replication. We herein report a recent 
discovery we have made regarding the antiviral activity 
of certain nucleotide derivatives, which may facilitate 
the development of new antiviral compounds. 
We [3-61 and others [7-91 have pursued a masked 
phosphate approach in an attempt to improve on the 
therapeutic potential of the parent nucleoside ana- 
logues. In this approach, inactive phosphate derivatives 
of the nucleoside analogue are designed to penetrate the 
cell membrane and liberate the bio-active nucleotides 
intracellularly. Masking of the phosphate group is nec- 
essary on account of the extremely poor membrane pen- 
etration by the polar (charged) free nucleotide. As we 
have noted [3] such masked pro-drugs may have im- 
proved antiviral selectivity by two quite separate means. 
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The most straightforward mechanism of enhanced se- 
lectivity is selective phosphate cleavage; could the phos- 
phate blocking group be designed to allow selective hy- 
drolysis and nucleotide release in the viral-infected cell? 
We have pursued this idea, with some success, by the 
synthesis of some phosphoramidate derivatives, with 
the phosphate blocked with amino acids [4]. The second 
mechanism by which masked phosphates may lead to 
enhanced selectivity of action arises from what we have 
termed ‘kinase bypass’ [3]. Thus, the complete depend- 
ence of administered (anti-HIV) nucleoside analogues 
on host nucleoside-kinase mediated activation places 
constraints upon the structures of nucleoside analogues 
which might be active. Nucleoside analogues which fall 
outside these strict constraints will be inactive, even if 
their S-triphosphates (the bio-active form) are potent 
and selective inhibitors of a viral target, such as reverse 
transcriptase (RT). Several such cases are known. For 
example 3’-O-methylthymidine (lb), an analogue of 
zidovudine, is inactive against HIV, whilst its tri- 
phosphate is an exceptionally potent inhibitor of HIV 
RT [lo]; the inactivity of the nucleoside being attributed 
to poor phosphorylation by host kinases. Dideoxythy- 
midine itself is another example of a 3’-modified nucle- 
oside which has low anti-viral activity on account of its 
poor phosphorylation. If the masked phosphate strat- 
egy were able to deliver nucleotides intracellularly, the 
nucleoside kinase would be by-passed and the structural 
constraints such host enzymes impose would be obvi- 
ated. In this way, wider structural variation of the nucle- 
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oside analogue would be permitted, and more specific 
(less toxic) inhibitors of viral function may arise. 
We now report the success of this strategy. In partic- 
ular, we have been able to demonstrate that judicious 
phosphorylation of certain inactive nucleoside ana- 
logues leads to the introduction of a significant, selec- 
tive antiviral effect. Moreover, such non-AZT deriva- 
tives are fully active against several AZT-resistant 
strains of virus; this could be another major advantage 
of the by-pass strategy. 
2. MATERIALS AND METHODS 
2.1. Chemistry 
General synthetic procedures were similar to those we have de- 
scribed [5]. Full details are given for compound (3b); subsequent com- 
pounds were similarly prepared and characterised. All materials were 
pure by high-field multi-nuclear NMR and reverse phase High Per- 
formance Liquid Chromatography (HPLC). 3’0mesylthymidine 5’- 
bis(2,2,2-trichloroethyl)phosphate (3b). A solution of methane sul- 
phony1 chloride (0.048 g, 0.42 mmol) in dry dichloromethane (5 ml) 
was added to a mixture of thymidine 5’-bis(2,2,2-trichlo- 
roethyl)phosphate (3a) (0.19 g, 0.32 mmol) and triethylamine (0.045 
g, 0.45 mmol) in dichloromethane (20 ml) with stirring at -20°C. The 
mixture was allowed to warm to ambient temperature, with stirring 
for 30 min, and was washed with saturated sodium bicarbonate solu- 
tion (4 x 50 ml) and saturated brine (2 x 50 ml). The organic phase was 
dried (MgSO,) and evaporated under reduced pressure, to yield the 
product as a white solid (0.11 g, 52%) m.p. 72-74°C. 8r (CDCl,) -4.8; 
S, (CDCl,) 165.3 (C2), 151.2 (C4), 137.2 (C6), 111.3 (C5), 95.1 (d, 
Ccl,, J = 11.2 Hz), 86.3 (Cl’), 82.7 (d, C4’, J = 7.6 Hz), 79.3 (C3’), 
77.7(d, CH,OP, J = 4.3 Hz), 68.2 (d, C5’, J = 6.0 Hz), 37.5 (MeSOd, 
37.1 (C2’), 11.8 (5-Me); Su (CDCI,) 8.9 (lH, bs, NH), 7.3 (lH, s, H6), 
6.3 (lH, dd, Hl’), 5.4 (lH, m, H3’),4.7 (4H, m, CH,OP), 4.4 (3H, m, 
H4’, H5’), 3.1 (3H, s, MeSO,), 2.6 (lH, m, H2’), 2.4 (lH, m, H2’), 1.9 
(3H, s, 5-Me); FAB MS m/e 667 (MH2+, 3 x “Cl, 3%), 666 (2), 665 (7), 
664 (3), 663 (8), 662 (2), 661 (MH’, 4), 303 (8) 207 (6) 127 (1 I), 81 
(C5H50+, 100); Found C 27.118, H 2.92, N 3.79, P 4.29, 
C,,H&l,N,O,$S ‘[HzO]o.25 requires C 26.99%, H 2.87, N 4.19, P 
4.64; Analytical HPLC retention time 30.54 min [ACS system, 50 + 
250 mm x 4.6 mm, Spherisorb 0DS2 5 p column, gradient elution 
using 5% acetonitrile in water (A), and 5% water in acetonitrile (B), 
with 20% B for c-10 min, then a linear gradient o 80% B at 30 min, 
with a flow rate of 1 mYminI. 
2.2. Virology 
Compounds were assayed for anti-HIV activity as described [l 11. 
0 
HO R-O-LO 
6 
A 
Z 
la Z= N3 
lb Z=Ohle 
lc Z=0SO&le 
Id Z=OAc 
le Z=OEt 
N3 
2a R=Et 
2b R = nPr 
2c R = nBu 
2d R = G13CCH2 
2e R = F3CCH2 
High titre virus stocks of the human immunodeficiency virus HIV-l aF 
were grown in H9 cells with RPM1 1640 (Flow Laboratories) supple- 
mented with 10% fetal calf serum and penicillin (100 IU /ml) and 
streptomycin (100 &ml). Cell debris was removed by low speed cen- 
trifugation, and the supernatant stored at -70°C until required. In a 
typical assay C8166 T-lymphoblastoid CD4+ cells were incubated 
with 10 TCIDSO HIV-l at 37°C for 90 min and then washed three 
times with phosphate-buffered saline (PBS). Cell aliquots (2 x 105) 
were resuspended in 1.5 ml growth medium in 6 ml tubes, and com- 
pounds at half log dilutions [200 to 0.1 PM] were added immediately. 
The nucleotides were sparingly soluble in aqueous solution, and 20 
mM stock solutions of each compound were made up in DMSO. The 
final DMSO concentration in the tissue culture medium was 1%. The 
cells were incubated at 37°C in 5% CO*. At 72 h post-infection 200 
~1 of supernatant was taken from each culture and assayed for HIV 
using an antigen capture ELISA [1 1] which recognises all of the core 
proteins equally (Coulter Electronics Ltd., Luton, UK). The ELISA 
plates were read with a spectrophotometer. The following controls 
were used: supernatants taken from infected and uninfected cells, 
infected cells treated with AZT (Roche Products UK, Ltd.) and ddC 
(Roche Products UK, Ltd.). The activities of AZT and ddC in infected 
cells gave I&, values of 10-20 nM and 200 nM respectively. Com- 
pounds were tested in duplicate at each concentration and experiments 
were carried out on at least 2 different occasions. The same protocols 
were used to evaluate HIV-l,, and the AZT-sensitive and resistant 
strains of HIV-l in the MT2 cells. The 018/A and 105/A sensitive 
strains were isolated before treatment with AZT. The 018/C resistant 
strain was isolated 6 months after treatment [12]. The 105-F strain was 
isolated after 136 weeks of treatment and contained 4 mutations in the 
RT coding region [13]. To test for compound toxicity aliquots of 2 x 
10’ uninfected cells were cultured with the compounds at the same log 
dilutions for 72 h. The cells were then washed with PBSA and resus- 
pended in 200 ~1 of growth medium containing 14C protein hydroly- 
sate. After 12 h the cells were harvested and the “C incorporation 
measured. Uninfected, untreated cells were used as controls. The com- 
pounds (la4c) showed a range of antiviral activities (IC,, values: 
Table I), whilst most were non-toxic (CC,, values) in this system at 
the highest concentration tested (100 or 200 PM). 
3. RESULTS AND DISCUSSION 
A labile phosphate group is clearly a pre-requisite for 
the masked phosphate approach, in order to facilitate 
(intracellular) release of the free nucleotides. Thus, sim- 
ple dialkyl phosphate derivatives (2a-c) of zidovudine 
are extremely resistant to phosphate hydrolysis, and 
they display no antiviral effect [3]. On the other hand 
Cl3C-CH2-O-7-0 Cl&-CHp-0-y-O 
? P 
9H2 CH2 
3a Z=OH 
3b 2 = 0S02Me 
3c z=oAc 
34 Z=OEt 
4a Z=OH 
4b Z= OS02Me 
4c z=oAc 
Fig. 1. The structures of potential anti-HIV nucleoside and nucleotide analogues. 
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bis(trihaloethy1) phosphate derivatives of zidovudine 
(2d,e) and of 2’,3’-dideoxycytidine (ddC) show signifi- 
cant lability towards hydrolysis [14], and are potent 
inhibitors of viral proliferation [5]. We now note that 
one of these phosphate masking groups, the 2,2,2- 
trichloroethyl moiety is successful in the kinase by-pass 
activation of certain inactive 3’-modified nucleosides. 
The first 3’-modification studied was the methane- 
sulphonyl (mesyl) group. It has been shown [lo] that 
3’-mesyl nucleosides have little or no anti-HIV activity, 
and it was of interest o probe the potential introduction 
of activity by suitable phosphorylation and consequen- 
tial kinase by-pass. One potential interest of the mesyl 
group is its leaving-group ability, which could lead to 
irreversible modification (suicide) if such a nucleotide 
(or a metabolite thereof) were to bind to the active site 
of a (viral) enzyme. Thus, thymidine was allowed to 
react with bis(2,2,2-trichloroethyl) phosphorochlori- 
date in pyridine at low temperature to give (3a) as we 
have described [5]. This was selectively mesylated at the 
3’-position by treatment with mesyl chloride in dichlo- 
romethane to give target compound (3b) in moderate 
yield. This was fully characterised by heteronuclear 
NMR, FAB mass spectrometry, and HPLC, all data 
being consistent with its structure and purity. The next 
3’-modification studied was the acetyl group. A particu- 
lar interest here is the possibility of esterase-induced 
cleavage of the acetyl function [ 151 providing a potential 
de-toxification route, since it would liberate thymidine 
nucleotides. Much of the selectivity of the anti-cancer 
nucleoside analogues FU and FUDR is now attributed 
to a more rapid metabolic breakdown in normal cells 
[16]. Thus, 3’-acetyl thymidine was prepared by stand- 
ard methods [17] and was allowed to react with 
bis(trichloroethy1) phosphorochloridate to give target 
compound (3~) in good yield. 
As discussed above, the metabolic instability of the 
mesyl and acetyl groups could be of therapeutic interest. 
However, it was of value to study also stable 3’-modifi- 
cations, the ether moiety being suitable. Thus, 3’-0- 
ethyl thymidine (le) was prepared from thymidine in 
three steps by the alkylation of S-trityl thymidine [18]. 
The nucleoside analogue (le) was then phosphorylated 
as usual to give the masked nucleotide (3d). 
Each of the parent nucleosides (la, 1c-e) and the 
corresponding masked phosphates (3b-d) were tested 
for their ability to inhibit the replication of HIV-l in 
C8166 T-cells, data being presented in the table. It is 
apparent that whilst the parent nucleosides (lc-e) are 
devoid of antiviral activity at the highest concentrations 
tested (lOO-200pM), the phosphate derivatives (3b-d) 
exert a significant anti-HIV effect at concentrations as 
low as 8pm. In a subsequent assay, compounds (3b-d) 
were noted to be of similar potency in a second cell line 
(MT2). There remains a significant antiviral effect in 
every case, with activity noted at non-cytotoxic concen- 
trations. Surprisingly, there is little variation in activity 
with variation in the 3’-substituent, although this is a 
limited study; further 3’-modifications are being studied 
in our laboratories at the moment. 
Analogues of 2’-deoxyuridine are ordinarily poorly 
active against HIV, this being either due to poor phos- 
phorylation, or poor interaction of the 5’-triphosphate 
with viral RT, or a combination of both. It was of 
interest to examine the activity of masked phosphate 
derivatives of inactive deoxyuridine nucleoside ana- 
logues [19]. Thus, the 5’-bis(trichloroethy1) phosphate 
of 2’-deoxyuridine (4a) was prepared as described 
above, and was mesylated and acetylated to give (4b) 
and (4c), respectively. As noted in the table, these com- 
pounds are of very limited antiviral activity, in each case 
being significantly less active than the corresponding 
Table I 
Anti-HIV-l and cvtotoxic effects of nucleoside and nucleotide analogues 
Cell: 
Virus: 
C8166 MT2 MT2 MT2 
RF RF Res018 SensOll ReslOSF SenslOSA 
IC,, CC,, ICYI CC,, IGO IGO Ratio ICSO IC,” Ratio 
Sample 
la 
lc 
Id 
le 
3b 
3c 
3d 
4b 
4c 
0.02 
> 100 
>lOO 
100 
8 
35 
28 
>lOO 
> 100 
500 0.04 
>lOO 
> 100 
> 100 _ 
> 100 45 
> 100 30 
150 30 
> 100 200 
> 100 > 200 
> 200 0.9 0.002 450 0.2 0.003 67 
_ _ _ _ _ 
_ _ _ _ 
_ _ _ _ 
> 200 110 100 1.1 80 105 0.8 
200 55 80 0.7 50 45 1.1 
200 24 24 1 40 52 0.8 
>200 > 200 110 > 1.8 90 100 0.9 
> 200 >200 100 >2 100 100 1 
The antiviral activity and cytotoxicity of test compounds. ICSo represents the concentration of compound (in ,DM) that decreases viral antigen 
production in infected cells to 50% of control. CC& represents the concentration of compound (inpM) which causes 50% cytotoxicity to uninfected 
cells (protein hydrolysate assay). 
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thymidine analogue. This would suggest that subse- 
quent phosphorylation steps from the mono- to tri- 
phosphate are inefficient in this case, or alternatively 
that the triphosphate is not a potent inhibitor of RT. 
Moreover, these data would suggest he base moiety to 
be important for activity, and would make it unlikely 
that antiviral action arises simply from the 
bis(trichloroethy1) phosphate group. 
Each of the compounds (la), (3bd), and (4h-c) were 
tested for their ability to inhibit viral proliferation using 
a range of AZT-sensitive and AZT-resistant isolates. 
Whereas the I&, values for AZT were increased 66 
450-fold for the two resistant isolates, the activity of the 
phosphate derivatives (3&l) was not affected by the 
transition. There is very clearly no cross-resistance be- 
tween AZT and the kinase-bypass compounds. This is 
entirely as expected, since the scope of AZT resistance 
appears to be restricted to nucleosides carrying azide 
groups at the sugar 3’-position. Indeed, one major ad- 
vantage of the by-pass approach may be the opportu- 
nity to utilise a wide range of different structures, in 
order to reduce the emergence of resistance. Although 
the structural variation we herein describe is limited to 
modifications at the 3’-position of the sugar, it appears 
likely that the by-pass approach may be applicable to 
modifications elsewhere in the sugar, or base regions. 
In conclusion, we report the antiviral activity of cer- 
tain masked phosphate derivatives of inactive 3’-modi- 
fied nucleosides, and attribute this introduction of activ- 
ity to kinase by-pass. It is quite likely that the use of 
alternative nucleosides and/or phosphate blocking 
groups may yield yet more potent anti-HIV agents, and 
it has not escaped our attention that this discovery may 
have implications in other aspects of chemotherapy. 
Lastly, we note that the increased structural freedom 
which arises from the by-pass approach may have impli- 
cations for dealing with the emergence of resistant 
strains of viruses. 
Acknowledgements: We thank the AIDS Directed Programme of the 
Medical Research Council for financial support. The Virology Group 
also thanks Roche Products UK Ltd. for support. CN and SRN thank 
the SERC for Studentships. 
REFERENCES 
[l] Furman, P.A., Fyfe, J.A., St. Clair, M.H. et al. (1986) Proc. Natl. 
Acad. Sci. USA 83, 8333-8337. 
[2] Larder, B.A and Kemp, S.D. (1989) Science 246, 1155-l 158. 
[3] McGuigan, C., Nicholls, S.R., O’Connor, T.J. and Kinchington, 
D. (1990) Antiviral Chem. Chemother. 1, 25-33. 
[4] McGuigan, C., Devine, K.G., O’Connor, T.J., and Kinchington 
D. (1991) Antiviral Res. 15, 255-263. 
[5] McGuigan, C., O’Connor, T.J. , Nicholls, S.R., Nickson, C. and 
Kinchington, D. (1990) Antiviral Chem. Chemother. 1,355-360. 
[6] McGuigan, C., Pathirana, R.N., Mahmood, N., Devine, K.G. 
and Hay, A.J. (1992) Antiviral Res. 17, 311-321. 
[7] Farrow, S.N., Jones, AS., Kumar, A., Walker, R.T., Balzarini, 
J. and De Clercq, E. (1990) J. Med. Chem. 33, 140&1406. 
[8] Gouyette, C., Neumann, J.M., Fauve, R. and Huynh-Dinh, T. 
(1989) Tetrahedron Lett. 30, 60196022. 
[9] Henin, Y., Gouyette, C., Schwartz, O., Debouzy, J.C., Neumann, 
J.M. and Huynh Dinh, T. (1991) J. Med. Chem., 34, 1830-1837. 
[lo] Herdewijn, P., Balzarini, J., De Clercq, E., Pauwels, R., Masa- 
nori, B., Broder, S. and Van der Haeghe, H. (1987) J. Med. Chem. 
30, 1270-1278. 
[1 1] Kinchington, D., Galpin, S.A., O’Connor, T.J., Jeffries, D.J. and 
Williamson, J.D. (1989) AIDS 3, 101-104. 
[l2] Larder, B.A., Darby, G. and Richman, D.D. (1989) Science 243, 
1731-1734. 
[l3] Boucher, C.A.B., O’Sullivan, E., Mulder, J.W., Ramautarsing, 
C., Kellam, P., Darby, G., Lange, J.M.A., Goudsmit, J. and 
Larder, B.A. (1992) J. Infect. Dis. 165, 105-110. 
[l4] see for example: McGuigan, C., Jones, B.C.N.M., Tollerfleld, 
S.M. and Riley, P.A. (1992) Antiviral Chem. Chemother. 3, 79- 
84. 
[15] Kawaguchi, T., Saito, M., Suzuki, Y., Nambu, N. and Nagai, T. 
(1985) Chem. Pharm. Bull. 33, 1652-1659. 
[l6] Mukherjee, K.L. and Heidelberger, C. (1960) J. Biol. Chem. 235, 
433437. 
[l7] Michelson, A.M. and Todd, A.R. (1953) J. Chem. Sot. 951-956. 
[l8] Hampton, A., Chawla, R.R. and Kappler, F. (1982) J. Med. 
Chem. 25, 644649. 
[l9] Balzarini, J., Kang, G.-J., Dalal, M., Herdewijn, P., De Clercq, 
E., Broder, S. and Johns, D.G. (1987) Mol. Pharmacol. 32, l62- 
167. 
252 
